ONESOURCE SPECL PHARMA L ONESOURCE NIFTY_SMALLNSEPHARMA
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 232.4% over 5 years.
- Profit CAGR of 30.3% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ONESOURCE ONESOURCE SPECL PHARMA L NIFTY_SMALLNSEPHARMA | 1,824.60 | - | ₹20,918.27 Cr | - | 0.45% | - | 232.38% | 30.26% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 425.95 Cr | 327.27 Cr | 375.76 Cr | 290.34 Cr | 428.22 Cr |
| Cost of Revenue | 110.91 Cr | 92.92 Cr | 113.49 Cr | 94.37 Cr | 146.26 Cr |
| Gross Profit | 315.05 Cr | 234.35 Cr | 262.27 Cr | 195.97 Cr | 281.95 Cr |
| Operating Expenses | 201.02 Cr | 213.67 Cr | 225.60 Cr | 248.29 Cr | 261.86 Cr |
| Operating Income | 114.02 Cr | 20.68 Cr | 36.67 Cr | -52.31 Cr | 20.09 Cr |
| EBITDA | 185.41 Cr | 90.88 Cr | 109.53 Cr | 14.86 Cr | 94.05 Cr |
| Interest Expense | 33.41 Cr | 27.48 Cr | 33.96 Cr | 38.23 Cr | 22.51 Cr |
| Pretax Income | 83.50 Cr | -4.40 Cr | 5.74 Cr | -93.01 Cr | -29.20 L |
| Tax Provision | -15.69 Cr | -4.21 Cr | -4.74 Cr | -4.31 Cr | -4.89 Cr |
| Net Income | 98.50 Cr | -18.60 L | 10.48 Cr | -88.70 Cr | 4.60 Cr |
| Diluted EPS | 8.59 | -0.02 | 0.91 | -7.74 | 0.40 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 38.71 Cr | 171.92 Cr | 1,444.85 Cr | 1,421.59 Cr |
| Cost of Revenue | 20.41 Cr | 70.51 Cr | 435.03 Cr | 444.65 Cr |
| Gross Profit | 18.30 Cr | 101.41 Cr | 1,009.82 Cr | 976.94 Cr |
| Operating Expenses | 234.19 Cr | 257.94 Cr | 817.19 Cr | 951.81 Cr |
| Operating Income | -215.88 Cr | -156.53 Cr | 192.63 Cr | 25.13 Cr |
| EBITDA | -261.44 Cr | -184.92 Cr | 373.14 Cr | 309.32 Cr |
| Interest Expense | 40.11 Cr | 85.40 Cr | 166.32 Cr | 122.19 Cr |
| Pretax Income | -415.64 Cr | -365.70 Cr | -67.07 Cr | -91.96 Cr |
| Tax Provision | 0 | 0 | -49.78 Cr | -18.16 Cr |
| Net Income | -799.83 Cr | -391.17 Cr | -17.97 Cr | -73.80 Cr |
| Diluted EPS | -69.89 | -34.18 | -1.63 | - |
Compounded Sales Growth
| 5 Years: | 232.38% |
| 1 Year: | -26.00% |
Compounded Profit Growth
| 5 Years: | 30.26% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +1.28% |
| 6 Months: | +14.15% |
| 3 Months: | +37.81% |
| 1 Month: | +3.52% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 2,008.81 Cr | 1,308.61 Cr | 7,550.24 Cr | 8,210.01 Cr |
| Current Assets | 228.40 Cr | 176.38 Cr | 1,086.18 Cr | 1,425.94 Cr |
| Cash & Equivalents | 4.97 Cr | 6.47 Cr | 156.48 Cr | 35.68 Cr |
| Inventory | 133.16 Cr | 11.23 Cr | 158.06 Cr | 438.96 Cr |
| Receivables | 3.82 Cr | 55.24 Cr | 416.60 Cr | 690.22 Cr |
| Total Liabilities | 1,223.36 Cr | 912.90 Cr | 1,669.66 Cr | 2,378.72 Cr |
| Current Liabilities | 865.22 Cr | 630.59 Cr | 1,113.56 Cr | 1,441.97 Cr |
| Long Term Debt | 334.88 Cr | 271.59 Cr | 219.33 Cr | 563.70 Cr |
| Total Debt | 864.22 Cr | 571.17 Cr | 942.44 Cr | 1,503.94 Cr |
| Total Equity | 785.45 Cr | 395.71 Cr | 5,880.58 Cr | 5,831.29 Cr |
| Shares Outstanding | 11.44 Cr | 11.44 Cr | 11.44 Cr | 11.46 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | -162.76 Cr | -107.21 Cr | -67.85 Cr | 8.52 Cr |
| Investing Cash Flow | -67.83 Cr | 510.55 Cr | -201.08 Cr | -494.98 Cr |
| Financing Cash Flow | 118.32 Cr | -390.54 Cr | 412.01 Cr | 359.44 Cr |
| Capital Expenditure | -43.99 Cr | -63.77 Cr | -128.15 Cr | -569.07 Cr |
| Free Cash Flow | -206.76 Cr | -170.98 Cr | -196.00 Cr | -560.55 Cr |
| Net Change in Cash | -112.28 Cr | 12.79 Cr | 143.07 Cr | -127.02 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 47.3% | 59.0% | 69.9% | 68.7% |
| Operating Margin % | -557.6% | -91.0% | 13.3% | 1.8% |
| Net Margin % | -2,066.0% | -227.5% | -1.2% | -5.2% |
| ROE % | -101.8% | -98.9% | -0.3% | -1.3% |
| ROCE % | -18.9% | -23.1% | 3.0% | 0.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ONESOURCE